Dr. Kumar
Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS, is the director of the rheumatology fellowship training program at the University of Iowa, Iowa City, and the physician editor of The Rheumatologist. Follow him on X (formerly Twitter) @BharatKumarMD.
This review highlights some of the many abstracts on lupus nephritis research presented at ACR Convergence 2025. They demonstrate advances made on early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.
Reckless approach versus missed opportunity?
Urine biomarkers have the potential to change how lupus nephritis is managed, serving as a noninvasive means of early detection, assessing treatment response and more.
Urinary biomarkers may have the potential to detect early treatment responses or failures in patients with lupus nephritis, according to Andrea Fava, MD. He and other experts discussed the latest research into lupus nephritis and how apply the recent ACR guideline to refractory cases.